Biogen (NASDAQ:BIIB) and Eisai Co., Ltd (TYO:4523) has just had their Alzheimer’s disease drug Aduhelm approved by the FDA on June 7, 2021. Investors holding the stock on Friday June 4 had their shares close at $286.14, and finished off Monday afternoon on June 7 at $395.85 per share. With such a massive increase in share price in one day, it’s one of the most lucrative FDA approvals of the year. Since June 4, the stock is up 33%. It was a big win for investors in a situation where many believed the FDA approval for Aduhelm would ...
Read The Full Article On StreetSignals.com
Get the latest stock market news on StreetSignals . Follow public companies and get free stock research reports and stock market analysis data and stock tips.
All content provided by StreetSignals is subject to our Terms Of Use and Disclaimer .
For further details see:
FDA Approves Biogen’s (NASDAQ:BIIB) New Alzheimer Drug